H

Hansoh Pharmaceutical Group Company Ltd
HKEX:3692

Watchlist Manager
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Watchlist
Price: 18.2 HKD 2.13% Market Closed
Market Cap: 108B HKD
Have any thoughts about
Hansoh Pharmaceutical Group Company Ltd?
Write Note

Hansoh Pharmaceutical Group Company Ltd
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hansoh Pharmaceutical Group Company Ltd
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cash from Investing Activities
ÂĄ1.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cash from Investing Activities
ÂĄ7B
CAGR 3-Years
N/A
CAGR 5-Years
61%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cash from Investing Activities
-ÂĄ1.9B
CAGR 3-Years
N/A
CAGR 5-Years
9%
CAGR 10-Years
-25%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cash from Investing Activities
-ÂĄ1.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
3%
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Cash from Investing Activities
-ÂĄ923.7m
CAGR 3-Years
N/A
CAGR 5-Years
2%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cash from Investing Activities
-ÂĄ81.9m
CAGR 3-Years
27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hansoh Pharmaceutical Group Company Ltd
Glance View

Market Cap
108B HKD
Industry
Pharmaceuticals

Nestled in the heart of China's burgeoning pharmaceutical industry, Hansoh Pharmaceutical Group Company Ltd. stands as a beacon of innovation and resilience. Founded in 1995, Hansoh has carved a niche for itself by focusing on the development, manufacturing, and distribution of a diverse portfolio of drugs. The company has garnered attention by zeroing in on therapeutic areas such as oncology, central nervous system disorders, anti-infectives, and diabetes, aiming to address the pressing needs of a growing patient population. This targeted strategy has not only positioned Hansoh as a formidable player in China's pharmaceutical landscape but also allowed it to compete on a global scale through its commitment to high-quality and affordable healthcare solutions. Hansoh's business model revolves around two core components: research and development (R&D) and strategic distribution. The company has invested heavily in R&D, maintaining an extensive pipeline of innovative drugs that promise to bolster its revenue streams. By focusing on a mix of generic and proprietary medications, Hansoh capitalizes on both established market demands and emerging medical needs. Additionally, its robust distribution network ensures that its products reach a broad array of hospitals and pharmacies, both within China and beyond. This dual approach of scientific advancement paired with efficient delivery mechanisms underpins Hansoh's business success, allowing it to generate steady revenues while paving the way for future growth in international markets.

Intrinsic Value
16.34 HKD
Overvaluation 10%
Intrinsic Value
Price
H

See Also

What is Hansoh Pharmaceutical Group Company Ltd's Cash from Investing Activities?
Cash from Investing Activities
1.1B CNY

Based on the financial report for Dec 31, 2023, Hansoh Pharmaceutical Group Company Ltd's Cash from Investing Activities amounts to 1.1B CNY.

Back to Top